Centrifuge
Usual
Sample is stable for up to 14 days at 2-8°C for up to 14 days. Sample is stable for up to 6 months at -20°C
In females, FSH stimulates follicle development and production of oestradiol and other oestrogens during the follicular phase of the menstrual cycle. FSH acts synergistically with LH to cause ovulation. In males FSH stimulates spermatogenesis. Increased concentrations of the gonadotrophins are seen in ovarian failure in women, whether pathological or after the natural menopause. High concentrations of FSH are seen in azoospermic men and LH is increased if testosterone secretion is decreased.
Samples from patients receiving high biotin doses (i.e. >5 mg/day) should be taken at least 8 hours post dose. In rare cases, interference due to extremely high titers of antibodies to analyte‑specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design, however, please interpret results in conjunction with the patients medical history, clinical examination and other findings, and contact the laboratory if interference is suspected. Please also inform the laboratory if the patient has been treated with monoclonal mouse antibodies or may have received them for diagnostic purposes.
Follicle Stimulating Hormone (FSH), like Luteinising Hormone (LH), belongs to the gonadotropin family. They synergistically regulate and stimulate the growth and function of the ovaries and testes. FSH is secreted by the anterior pituitary in response to gonadotrophin releasing hormone (GnRH) secreted by the hypothalamus. In both males and females, FSH secretion is regulated by a balance of positive and negative feedback mechanisms involving the hypothalamic-pituitary axis, the reproductive organs, and the pituitary and sex steroid hormones.
Males
0.95 - 11.95 IU/L
Females
Follicular phase: 3.03 - 8.08 IU/L
Mid-cycle: 2.55 - 16.69 IU/L
Luteal phase: 1.38 - 5.47 IU/L
Post-menopausal: 26.72 - 133.41 IU/L
NEQAS
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962